---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-033066"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:59:59.356390+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics FY2022 net loss $130.9M; cash runway extended into 2026

## Summary
- Net loss of $130.9M for FY2022 vs $95.8M in FY2021; R&D expenses $97.2M (up 29%).
- Cash, cash equivalents, and investments: $367.4M as of Dec 31, 2022; cash runway into 2026.
- Collaboration revenue from BMS: $5.2M for FY2022.
- Phase 1 ELiPSE-1 trial of CNTY-101 dosed first patient in Feb 2023; initial data by year-end 2023.
- FY2023 GAAP operating expense guidance: $135M-$145M, incl. $12M-$17M stock-based comp.

## SEC filing metadata
- accession: 0001104659-23-033066
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465923033066/0001104659-23-033066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465923033066/tm239540d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-033066
- JSON: https://secwatch.observer/filing/0001104659-23-033066.json
- Plain text: https://secwatch.observer/filing/0001104659-23-033066.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported the full-year ended December 31, 2022 results: revenue $5.2 million, net income $130.9 million. Guidance reaffirmed.
  - Period: the full-year ended December 31, 2022
  - Revenue: $5.2 million
  - Net income: $130.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: of $118.0 million), compared to net cash used in operations of $89.0 million for the twelve months ended December 31, 2021. · Collaboration Revenue: Collaboration revenue was $5.2 million for the twelve months ended December 31, 2022, generated through the Company’s collaboration, option and license agreement with BMS. · Research and Development (R&D) expenses :
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465923033066/0001104659-23-033066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.